Ravil R Petrov

US Patent:

20120039804, Feb 16, 2012

Filed:

Jun 6, 2011

Appl. No.:

13/154234

Inventors:

Philippe Diaz - Missoula MT, US
Fanny Diaz - Missoula MT, US
Ravil Rashitovich Petrov - Missoula MT, US

International Classification:

A61K 31/454
C07D 209/88
A61K 31/403
C07D 417/10
A61K 31/541
A61P 25/00
A61P 35/00
A61P 17/00
A61P 3/00
A61P 25/30
A61P 25/18
A61P 25/28
A61P 19/08
A61P 29/00
A61P 17/06
A61P 17/04
A61P 3/04
A61K 49/00
C07D 401/10

US Classification:

424 91, 546200, 514323, 548441, 514411, 544 582, 5142282

Abstract:

The compounds of the invention are modulators of cannabinoid receptors CB1 or CB2. The compounds can be used for the prevention or treatment of, e.g., pain, cancer, skin diseases, weight-associated disorders, chemical addictions, psychiatric disorders, neurodegenerative disorders, bone diseases, and inflammatory diseases. The compounds of the invention can further be used to study these diseases and disorders, as well as cannabinoid receptor biology, by coupling the compounds to, e.g., imaging agents.

US Patent:

20170096426, Apr 6, 2017

Filed:

Oct 7, 2016

Appl. No.:

15/288592

Inventors:

- Missoula MT, US
Fanny Diaz - Missoula MT, US
Ravil R. Petrov - Missoula MT, US

International Classification:

C07D 471/04
G01N 33/94
C07D 405/06
C07D 401/06
C07D 209/88
C07D 209/82

Abstract:

The compounds of the invention are modulators of cannabinoid receptors CB1 or CB2. The compounds can be used for the prevention or treatment of, e.g., pain, cancer, skin diseases, weight-associated disorders, chemical addictions, psychiatric disorders, neurodegenerative disorders, bone diseases, and inflammatory diseases. The compounds of the invention can further be used to study these diseases and disorders, as well as cannabinoid receptor biology, by coupling the compounds to, e.g., imaging agents.